Skip to main content
SpringerLink
Log in

Osteonecrosis of the Jaw

  • Chapter
  • First Online:
Book cover Myeloma Bone Disease

Part of the book series: Current Clinical Oncology ((CCO))

  • 868 Accesses

Abstract

Osteonecrosis of the jaw (ONJ), defined as an oral soft tissue defect with superficial necrosis of the underlying exposed bone, is a severe but uncommon side effect of bisphosphonates (BP). ONJ typically follows a mucosal injury, such as a dental extraction. The exact incidence is unknown but seems to range between 3 and 4%. ONJ occurs after a median of 4 years of “continuous” BP use. There is no specific therapy and 60% of the patients will heal spontaneously in 6–9 months. It seems reasonable to stop BP once ONJ develops until the mucosal lesions heal and then restart BP if clinically indicated; stopping BP before dental procedures is recommended. The use of pamidronate rather than zoledronic acid and less frequent infusions 3-monthly after the first 2 years of monthly infusions may decrease the risk of ONJ, although definitive data are absent. Implementation of preventative measures such as good dental hygiene and limiting the invasiveness of dental procedures seems to decrease the risk of ONJ. Pathogenesis of BP-induced ONJ is unknown. In this chapter, the incidence and risks of ONJ, the clinical presentation, diagnostic workup will be reviewed followed by a summary of the current hypotheses of pathogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol. 2007;4:42–55.

    Article  CAS  PubMed  Google Scholar 

  2. Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T. Zoledronic acid – a multiplicity of anti-cancer action. Curr Med Chem. 2007;14:2126–2135.

    Article  CAS  PubMed  Google Scholar 

  3. Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008;9:1166–1172.

    Article  PubMed  Google Scholar 

  4. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J. 2003;48:268.

    Article  CAS  PubMed  Google Scholar 

  5. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1117.

    Article  PubMed  Google Scholar 

  6. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62: 527–534.

    Article  PubMed  Google Scholar 

  7. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2009;122:S33–S45.

    Article  CAS  PubMed  Google Scholar 

  8. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369–376.

    Google Scholar 

  9. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44:857–869.

    Article  CAS  PubMed  Google Scholar 

  10. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479–1491.

    Google Scholar 

  11. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006;24:945–952.

    Article  CAS  PubMed  Google Scholar 

  12. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006;137:1144–1150.

    Google Scholar 

  13. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2007;65:1328–1331.

    Article  PubMed  Google Scholar 

  14. Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol. 2007;18:2015–2019.

    Article  CAS  PubMed  Google Scholar 

  15. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–836.

    Google Scholar 

  16. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580–8587.

    Article  PubMed  Google Scholar 

  17. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol. 2006;134:620–623.

    Article  CAS  PubMed  Google Scholar 

  18. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99–102; discussion 199–102.

    Article  CAS  PubMed  Google Scholar 

  19. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst. 2007;99:1016–1024.

    Article  CAS  PubMed  Google Scholar 

  20. Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc. 2008;139:23–30.

    PubMed  Google Scholar 

  21. Badros A, Terpos E, Katodritou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol. 2008;26:5904–5909.

    Article  PubMed  Google Scholar 

  22. Phal PM, Myall RW, Assael LA, Weissman JL. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. Am J Neuroradiol. 2007;28:1139–1145.

    Article  CAS  PubMed  Google Scholar 

  23. Carneiro E, Vibhute P, Montazem A, Som PM. Bisphosphonate-associated mandibular osteonecrosis. Am J Neuroradiol. 2006;27:1096–1097.

    CAS  PubMed  Google Scholar 

  24. Wilde F, Steinhoff K, Frerich B, et al. Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(3):412–419.

    Article  PubMed  Google Scholar 

  25. Raje N, Woo SB, Hande K, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008;14: 2387–2395.

    Article  CAS  PubMed  Google Scholar 

  26. Garcia-Ferrer L, Bagan JV, Martinez-Sanjuan V, et al. MRI of mandibular osteonecrosis secondary to bisphosphonates. AJR Am J Roentgenol. 2008;190:949–955.

    Article  PubMed  Google Scholar 

  27. Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol. 2006;35:236–243.

    Article  CAS  PubMed  Google Scholar 

  28. Dore F, Filippi L, Biasotto M, Chiandussi S, Cavalli F, Di Lenarda R. Bone scintigraphy and SPECT/CT of bisphosphonate-induced osteonecrosis of the jaw. J Nucl Med. 2009;50:30–35.

    Article  PubMed  Google Scholar 

  29. Zanglis A, Andreopoulos D, Dima M, Baltas G, Baziotis N. Jaw uptake of technetium-99 methylene diphosphonate in patients on biphosphonates: a word of caution. Hell J Nucl Med. 2007;10:177–180.

    PubMed  Google Scholar 

  30. Yang KH, Won JH, Yoon HK, Ryu JH, Choo KS, Kim JS. High concentrations of pamidronate in bone weaken the mechanical properties of intact femora in a rat model. Yonsei Med J. 2007;48:653–658.

    Article  CAS  PubMed  Google Scholar 

  31. Meier C, Seibel MJ, Kraenzlin ME. Use of bone turnover markers in the real world: are we there yet? J Bone Miner Res. 2009;24:386–388.

    Article  PubMed  Google Scholar 

  32. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397–2410.

    Article  PubMed  Google Scholar 

  33. Badros A, Goloubeva O, Terpos E, Milliron T, Baer MR, Streeten E. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol. 2008;142(3): 492–494.

    Article  PubMed  Google Scholar 

  34. Lehrer S, Montazem A, Ramanathan L, et al. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg. 2009;67: 159–161.

    Article  PubMed  Google Scholar 

  35. Bagan JV, Jimenez Y, Gomez D, Sirera R, Poveda R, Scully C. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol. 2008;44:1088–1089.

    Article  CAS  PubMed  Google Scholar 

  36. Landesberg R, Cozin M, Cremers S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66:839–847.

    Article  PubMed  Google Scholar 

  37. Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol. 2009;144:667–676.

    Article  CAS  PubMed  Google Scholar 

  38. Yamada J, Tsuno NH, Kitayama J, et al. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res. 2009;151:115–120.

    Article  CAS  PubMed  Google Scholar 

  39. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302:1055–1061.

    Article  CAS  PubMed  Google Scholar 

  40. Hasmim M, Bieler G, Ruegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost. 2007;5:166–173.

    Article  CAS  PubMed  Google Scholar 

  41. Bezzi M, Hasmim M, Bieler G, Dormond O, Ruegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem. 2003;278:43603–43614.

    Article  CAS  PubMed  Google Scholar 

  42. Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13:4482–4486.

    Article  CAS  PubMed  Google Scholar 

  43. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003;9:2893–2897.

    CAS  PubMed  Google Scholar 

  44. Scavelli C, Di Pietro G, Cirulli T, et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther. 2007;6:3256–3262.

    Article  CAS  PubMed  Google Scholar 

  45. Bellahcene A, Chaplet M, Bonjean K, Castronovo V. Zoledronate inhibits alphavbeta3 and alphavbeta5 integrin cell surface expression in endothelial cells. Endothelium. 2007;14: 123–130.

    Article  CAS  PubMed  Google Scholar 

  46. Koto K, Horie N, Kimura S, et al. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett. 2009;274:271–278.

    Article  CAS  PubMed  Google Scholar 

  47. Allegra A, Oteri G, Nastro E, et al. Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol. 2007;25:164–169.

    Article  CAS  PubMed  Google Scholar 

  48. Napenas JJ, Brennan MT, Bahrani-Mougeot FK, Fox PC, Lockhart PB. Relationship between mucositis and changes in oral microflora during cancer chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:48–59.

    Article  PubMed  Google Scholar 

  49. Hansen T, Kunkel M, Springer E, et al. Actinomycosis of the jaws – histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch. 2007;451:1009–1017.

    Article  PubMed  Google Scholar 

  50. Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg. 2008;66:767–775.

    Article  PubMed  Google Scholar 

  51. Bahrani-Mougeot FK, Paster BJ, Coleman S, Ashar J, Barbuto S, Lockhart PB. Diverse and novel oral bacterial species in blood following dental procedures. J Clin Microbiol. 2008;46:2129–2132.

    Article  PubMed  Google Scholar 

  52. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20:117–120.

    Article  CAS  PubMed  Google Scholar 

  53. Sarasquete ME, Garcia-Sanz R, Marin L, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 2008;112: 2709–2712.

    Article  CAS  PubMed  Google Scholar 

  54. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42:1228–1236.

    Article  CAS  PubMed  Google Scholar 

  55. Cremers S, Sparidans R. den HJ, Hamdy N, Vermeij P, Papapoulos S. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol. 2002;57:883–890.

    Article  CAS  PubMed  Google Scholar 

  56. Khan SA, Kanis JA, Vasikaran S, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res. 1997;12:1700–1707.

    Article  CAS  PubMed  Google Scholar 

  57. Bone HG, Downs RW Jr, Tucci JR, et al. Dose–response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab. 1997;82:265–274.

    Article  CAS  PubMed  Google Scholar 

  58. Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT, Greig WR. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med. 1978;19:270–275.

    CAS  PubMed  Google Scholar 

  59. Allen MR. Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs. 2009;189:289–294.

    Article  CAS  PubMed  Google Scholar 

  60. Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol. 2009;45:164–172.

    Article  CAS  PubMed  Google Scholar 

  61. Van den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol. 2009;20:331–336.

    Article  PubMed  Google Scholar 

  62. Saussez S, Javadian R, Hupin C, et al. Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series. Laryngoscope. 2009;119:323–329.

    Article  CAS  PubMed  Google Scholar 

  63. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg. 2007;65:1321–1327.

    Article  PubMed  Google Scholar 

  64. Shimura K, Shimazaki C, Taniguchi K, et al. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol. 2006;84:343–345.

    Article  CAS  PubMed  Google Scholar 

  65. Petrucci MT, Gallucci C, Agrillo A, Mustazza MC, Foa R. Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients. Haematologica. 2007;92:1289–1290.

    Article  PubMed  Google Scholar 

  66. Stubinger S, Dissmann JP, Pinho NC, Saldamli B, Seitz O, Sader R. A preliminary report about treatment of bisphosphonate related osteonecrosis of the jaw with Er:YAG laser ablation. Lasers Surg Med. 2009;41:26–30.

    Google Scholar 

  67. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464–2472.

    Article  CAS  PubMed  Google Scholar 

  68. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81:1047–1053.

    Article  CAS  PubMed  Google Scholar 

  69. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005;104:83–93.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Greenebaum Cancer Center, University of Maryland, Baltimore, MD, 21201, USA

    Ashraf Badros (Associate Professor of Medicine)

Authors
  1. Ashraf Badros
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashraf Badros .

Editor information

Editors and Affiliations

  1. Dept. Medicine, University of Pittsburgh, Centre Avenue 5115, Pittsburgh, 15232, USA

    G. David Roodman

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Badros, A. (2010). Osteonecrosis of the Jaw. In: Roodman, G. (eds) Myeloma Bone Disease. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-60761-554-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-554-5_7

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-553-8

  • Online ISBN: 978-1-60761-554-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation